Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Caladrius Biosciences Q1 EPS $(0.07) Beats $(0.10) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share
byBill Haddad
May 5, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EV Craze Alters Auto Industry Landscape: Rivian Now More Valuable Than Volkswagen, Lucid Overtakes Ford’s Market Cap

By Shanthi Rexaline
Today, 8:43 AM
The EV revolution has pushed to the forefront nimble pureplay electric vehicle startups that have managed to win investor confidence in huge measure. This is evident in the massive valuation some have built up even as the companies are yet to start or have just started commercial operations.

AMZN